Print Page  |  Close Window

2017 Press Releases

Keyword Search
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
03/20/17Syros Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
– Presented Data at Key Medical Meetings Further Supporting Therapeutic Potential of SY-1425 in Genomically Defined AML, MDS and Breast Cancer Patients – – Highlighted Data at Scientific Conferences Demonstrating Productivity of Syros’ Gene Control Platform in Oncology and Immuno-oncology – – On Track to Report Initial Clinical Data on SY-1425 in Fall 2017 – – On Track to Initiate Phase 1 Clinical Trial of SY-1365 in ... 
Printer Friendly Version
03/01/17Syros to Present New Data on Lead Drug Candidates, SY-1425 and SY-1365, and CDK12/13 Inhibitor Program at Upcoming AACR Annual Meeting
Presentations Highlight Therapeutic Potential of Company’s Clinical and Preclinical Programs and Leadership in Gene Control CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 1, 2017-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of disease-driving genes, today announced that the Company will present new data on three of its clinical and preclinical programs at the Am... 
Printer Friendly Version
03/01/17Syros Pharmaceuticals to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 1, 2017-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of disease-driving genes, today announced that members of its management team will present at upcoming investor conferences. Details are as follows: Cowen and Company 37th Annual Health Care Conference Date: Wednesday, March 8 Presentation Time: 11:20 ... 
Printer Friendly Version
02/27/17Syros Reports Discovery of Novel Genomics Based Approach to Stratifying Patients with Acute Myeloid Leukemia at Cold Spring Harbor Conference
Analysis of the Regulatory Genome Provides New Approach for AML Patient Stratification Independent of Genomic Mutations Super-enhancers Shown to be Associated with Survival Outcomes and Response to Therapies in Development CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 27, 2017-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving ... 
Printer Friendly Version
02/21/17Syros’ Drug Discovery Research in Immuno-Oncology Highlighted at UCSD Moores Cancer Center Symposium
Company Identifies Alterations in the Regulatory Genome of Tumor-Associated Macrophages in Subset of Pancreatic Cancer Patient Tissues Findings Underscore the Promise of the Syros’ Gene Control Platform to Yield Important Insights into Thwarting Cancer’s Ability to Evade the Immune System CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 21, 2017-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the developmen... 
Printer Friendly Version
02/09/17Syros Announces Publication in Cell Highlighting Gene Control as Important and Rapidly Progressing Area of Research for Yielding New Medicines to Treat Cancer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 9, 2017-- Syros Pharmaceuticals (NASDAQ:SYRS) today announced the publication of a paper in a special cancer-focused issue of the scientific journal Cell that highlights gene control as an important area for cancer drug discovery and development, underscoring the promise of Syros’ pioneering approach to advance a new wave of medicines that control the expression of disease-driving genes. The paper, w... 
Printer Friendly Version
02/07/17Syros Pharmaceuticals to Present at 2017 BIO CEO & Investor Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 7, 2017-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of disease-driving genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the 2017 BIO CEO & Investor Conference. Details are as follows: 2017 BIO CEO & Investor Conference Date: Tuesday, Feb... 
Printer Friendly Version
01/30/17Syros Appoints Industry Leader Peter Wirth as Chair of Its Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 30, 2017-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of disease-driving genes, today announced the appointment of Peter Wirth as Chair of the Company’s Board of Directors. Mr. Wirth is an industry veteran with a track record of value creation in biotechnology. "Peter is a recognized leader in the biotech industry whose... 
Printer Friendly Version
01/10/17Syros to Present at the 35th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 10, 2017-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of disease-driving genes, today announced that its Chief Executive Officer Nancy Simonian, M.D., will present a corporate overview at the 35th Annual J.P. Morgan Healthcare Conference. Details are as follows: 35th Annual J.P. Morgan Healthcare Conference Date: ... 
Printer Friendly Version
01/09/17Syros Pharmaceuticals Announces 2017 Strategic Priorities and Goals
2016 Accomplishments Put Company on Track to Achieve Significant 2017 Clinical Milestones Initial Data Readout from Ongoing Phase 2 Clinical Trial of SY-1425, Its First-in-Class Selective RARα Agonist, in Subsets of AML and MDS Patients Expected in Fall of 2017 SY-1365, Its First-in-Class Selective CDK7 Inhibitor, Expected to Advance into Phase 1 Clinical Trial in First Half of 2017 Company Also Reveals New Preclinical Prog... 
Printer Friendly Version